Phase 2CompletedINTERVENTIONAL
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
ClinicalTrials.gov · NCT06139419 · Registry updated: 2026-08-03
- Condition / research focus
- Non-small Cell Lung Cancer
- Sponsor
- Sun Yat-sen University
- Countries with listed sites
- China
- Registry dates and results
- Start: 2023-07-25. Completion: 2026-06-30 (may be estimated). No results posted in this registry response.
Products and interventions (5)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- definitive radiotherapy (radiation)
- induction chemo-immunotherapy (drug) — also listed as: albumin-bound paclitaxel, cisplatin, tislelizumab
- concurrent chemotherapy (drug) — also listed as: albumin-bound paclitaxel, cisplatin
- Immunotheapy consolidation (drug) — also listed as: tislelizumab
- Thymosin Alpha1 (drug) — also listed as: thymalfasin
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Sun yat-sen university cancer center
Guangzhou, Guangdong, China
Site recruitment: Not reported